Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy

Research output: Contribution to journalArticle

Abstract

With recent approvals for multiple therapeutic antibodies that block cytotoxic T lymphocyte associated antigen 4 (CTLA4) and programmed cell death protein 1 (PD1) in melanoma, non-small-cell lung cancer and kidney cancer, and additional immune checkpoints being targeted clinically, many questions still remain regarding the optimal use of drugs that block these checkpoint pathways. Defining biomarkers that predict therapeutic effects and adverse events is a crucial mandate, highlighted by recent approvals for two PDL1 diagnostic tests. Here, we discuss biomarkers for anti-PD1 therapy based on immunological, genetic and virological criteria. The unique biology of the CTLA4 immune checkpoint, compared with PD1, requires a different approach to biomarker development. Mechanism-based insights from such studies may guide the design of synergistic treatment combinations based on immune checkpoint blockade.

Original languageEnglish (US)
Pages (from-to)275-287
Number of pages13
JournalNature Reviews Cancer
Volume16
Issue number5
DOIs
StatePublished - Apr 26 2016

Fingerprint

CTLA-4 Antigen
Kidney Neoplasms
Biomarkers
Programmed Cell Death 1 Receptor
Neoplasms
Therapeutic Uses
Routine Diagnostic Tests
Non-Small Cell Lung Carcinoma
Melanoma
Therapeutics
Antibodies
Pharmaceutical Preparations
Study Guide

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

@article{cceebe67ec5b472e90860a0f280c1464,
title = "Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy",
abstract = "With recent approvals for multiple therapeutic antibodies that block cytotoxic T lymphocyte associated antigen 4 (CTLA4) and programmed cell death protein 1 (PD1) in melanoma, non-small-cell lung cancer and kidney cancer, and additional immune checkpoints being targeted clinically, many questions still remain regarding the optimal use of drugs that block these checkpoint pathways. Defining biomarkers that predict therapeutic effects and adverse events is a crucial mandate, highlighted by recent approvals for two PDL1 diagnostic tests. Here, we discuss biomarkers for anti-PD1 therapy based on immunological, genetic and virological criteria. The unique biology of the CTLA4 immune checkpoint, compared with PD1, requires a different approach to biomarker development. Mechanism-based insights from such studies may guide the design of synergistic treatment combinations based on immune checkpoint blockade.",
author = "Suzanne Topalian and Taube, {Janis M} and Anders, {Robert A} and Pardoll, {Andrew Mark}",
year = "2016",
month = "4",
day = "26",
doi = "10.1038/nrc.2016.36",
language = "English (US)",
volume = "16",
pages = "275--287",
journal = "Nature Reviews Cancer",
issn = "1474-175X",
publisher = "Nature Publishing Group",
number = "5",

}

TY - JOUR

T1 - Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy

AU - Topalian, Suzanne

AU - Taube, Janis M

AU - Anders, Robert A

AU - Pardoll, Andrew Mark

PY - 2016/4/26

Y1 - 2016/4/26

N2 - With recent approvals for multiple therapeutic antibodies that block cytotoxic T lymphocyte associated antigen 4 (CTLA4) and programmed cell death protein 1 (PD1) in melanoma, non-small-cell lung cancer and kidney cancer, and additional immune checkpoints being targeted clinically, many questions still remain regarding the optimal use of drugs that block these checkpoint pathways. Defining biomarkers that predict therapeutic effects and adverse events is a crucial mandate, highlighted by recent approvals for two PDL1 diagnostic tests. Here, we discuss biomarkers for anti-PD1 therapy based on immunological, genetic and virological criteria. The unique biology of the CTLA4 immune checkpoint, compared with PD1, requires a different approach to biomarker development. Mechanism-based insights from such studies may guide the design of synergistic treatment combinations based on immune checkpoint blockade.

AB - With recent approvals for multiple therapeutic antibodies that block cytotoxic T lymphocyte associated antigen 4 (CTLA4) and programmed cell death protein 1 (PD1) in melanoma, non-small-cell lung cancer and kidney cancer, and additional immune checkpoints being targeted clinically, many questions still remain regarding the optimal use of drugs that block these checkpoint pathways. Defining biomarkers that predict therapeutic effects and adverse events is a crucial mandate, highlighted by recent approvals for two PDL1 diagnostic tests. Here, we discuss biomarkers for anti-PD1 therapy based on immunological, genetic and virological criteria. The unique biology of the CTLA4 immune checkpoint, compared with PD1, requires a different approach to biomarker development. Mechanism-based insights from such studies may guide the design of synergistic treatment combinations based on immune checkpoint blockade.

UR - http://www.scopus.com/inward/record.url?scp=84963621254&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84963621254&partnerID=8YFLogxK

U2 - 10.1038/nrc.2016.36

DO - 10.1038/nrc.2016.36

M3 - Article

C2 - 27079802

AN - SCOPUS:84963621254

VL - 16

SP - 275

EP - 287

JO - Nature Reviews Cancer

JF - Nature Reviews Cancer

SN - 1474-175X

IS - 5

ER -